DoD Tuberous Sclerosis Complex, Idea Development Award | W81XWH 19 TSCRP IDA

Frequently Asked Questions (FAQs)

1) What is the TSCRP Idea Development Award?

The Tuberous Sclerosis Complex Research Program (TSCRP) Idea Development Award (Funding Opportunity Number W81XWH-19-TSCRP-IDA) is a Department of Defense grant opportunity that supports conceptually innovative research projects in tuberous sclerosis complex (TSC). Its purpose is to open new directions in the field and produce high-impact results that could ultimately improve patient care.

2) What kinds of research projects is this award intended to support?

This mechanism is aimed at innovative research that goes beyond routine, next-step studies. Competitive projects are expected to rethink assumptions, introduce new approaches, or apply creative strategies that may be higher-risk but have the potential for substantial payoff in TSC science and/or clinical care.

3) What is the overall goal of the program?

The stated intent is to fund ideas that could lead to major advances in TSC science and, ultimately, meaningful improvements in patient care. Applicants are expected to clearly explain both the short-term and long-term significance of the proposed work.

4) Is a hypothesis required?

Yes. A central expectation is that the proposed work is anchored by a clear, well-formulated, and testable hypothesis. Innovation is encouraged, but applications should not be purely speculative.

5) Does the program require preliminary data?

Yes. Even though the award emphasizes innovation, applicants are expected to provide strong scientific rationale and preliminary data or other preliminary support. The opportunity seeks a balance between bold ideas and credible early evidence.

6) What counts as preliminary support for the proposed idea?

Preliminary support can include unpublished findings generated by the principal investigator (PI) or named collaborators, as well as relevant evidence from the published literature that directly informs the proposed TSC research question and approach.

7) How are applications evaluated?

Applications are evaluated heavily on impact and innovation. Proposals should clearly describe how successful completion would materially advance TSC research and/or clinical care (impact) and demonstrate how the work creates a new paradigm, challenges existing paradigms, or addresses established problems from a fresh angle (innovation).

8) What does the program mean by “impact”?

Impact refers to the expected significance of the research if it succeeds. Applicants are expected to articulate both short-term and long-term importance, including how the results would materially advance TSC research and/or contribute to meaningful improvements in clinical care.

9) What does the program mean by “innovation”?

Innovation is described as work that creates a new paradigm, challenges existing paradigms, or tackles established problems in a novel way. The mechanism is intended for research that changes thinking or approach, rather than simply extending an existing line of studies.

10) Are incremental or routine next-step studies competitive?

No. Projects characterized as incremental or as the next logical experiment in an existing line of research are specifically described as not competitive under this mechanism.

11) What is the New Investigator Option?

The funding announcement includes a New Investigator Option to grow the pipeline of TSC researchers. This track is intended for early-career investigators building an independent TSC research program and for established investigators who are transitioning into TSC from other fields.

12) How are New Investigator applications reviewed compared to Established Investigator applications?

New Investigator and Established Investigator applications are reviewed in separate pools. This is intended to help ensure early-career or field-transition applicants are evaluated relative to similar applicants.

13) Are New Investigators encouraged to collaborate?

Yes. New Investigators are strongly encouraged to strengthen proposals through collaboration with investigators who have demonstrated TSC expertise or other relevant specialized capabilities, typically evidenced by prior funding and publications.

14) Who is the sponsoring agency and administrative office for this opportunity?

The opportunity is offered by the Department of Defense, Department of the Army, through USAMRAA.

15) What is the CFDA number and category for this opportunity?

The opportunity is categorized as a discretionary funding opportunity within science and technology and other research and development activities, with CFDA 12.420.

16) What funding instruments are available under this opportunity?

The funding instruments listed include grants and cooperative agreements.

17) Who is eligible to apply?

Eligibility is described as unrestricted, meaning applications are generally open to many entity types, subject to any additional eligibility clarifications in the full announcement.

18) When was this opportunity created and what was the original closing date?

The opportunity was created on February 19, 2019, and the original closing date was May 9, 2019.

19) How many awards were anticipated?

The announcement anticipated making about three awards.

20) What is the maximum award amount (award ceiling) for this opportunity?

The summary data lists the award ceiling as 0. This typically indicates that applicants should consult the full program announcement for specific budgeting limits and any cost or duration guidance not captured in the abbreviated listing.

21) Where should applicants look for detailed budget limits and project duration guidance?

Because the award ceiling is listed as 0 in the summary information, applicants are expected to consult the full program announcement for the specific budgeting limits, allowable costs, and any cost or duration guidance.

22) Does the program support high-risk ideas?

Yes, the program favors creative, potentially higher-risk strategies, as long as they are grounded in strong scientific rationale and supported by preliminary data or other credible preliminary evidence.

23) What balance is the program looking for in proposed research?

The program is looking for bold, conceptually innovative ideas that are still grounded in credible early evidence, including preliminary data and/or published literature directly supporting the proposed TSC research question and approach.

24) What is the key message applicants should convey in the proposal narrative?

Based on the stated evaluation emphasis, applicants should clearly communicate: (a) a testable hypothesis, (b) the scientific rationale and preliminary support, (c) why the approach is genuinely innovative rather than incremental, and (d) how success would materially advance TSC science and/or improve patient care in the short and long term.